On January 8, 2025 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel, first-in-class biologic therapy to treat solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), reported a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI), being held January 23-25, 2025, in San Francisco, CA. Poster details are included below (Press release, Bexion, JAN 8, 2025, View Source [SID1234649518]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Details:
Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: January 25, 2025
Abstract Number: TPS320
Abstract Title: "BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 study."
More details on the conference can be found at the ASCO (Free ASCO Whitepaper) GI website at conferences.asco.org/gi/attend.
About BXQ-350
Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents.